Skip to main content
SpringerLink
Log in

Fibrinolysis and Fibrinolytic Drugs

  • Chapter
Book cover Pharmacology of the Skin II

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 87 / 2))

Abstract

Fibrinolysis, the physiologic process which performs the task of demolishing fibrin, is dependent on various activation and inhibtion mechanisms, and is subject to functional fluctuations in biorhythm (Fearnley 1966). The fibrinolytic system can be simply defined as “the enzymatic breakdown of fibrin to fragments which are no longer able to form a coherent fibrin net” (von Kaulla 1963). This system is part of a more substantial mechanism which creates in the cutaneous organ a dynamic balance between fibrinosynthesis and fibrinolysis, known as “the balance between fibrinolysis and fibrin deposition” (Ryan 1976). The equilibrium between fibrinosynthesis and fibrinolysis is a consequence of the activity of the inhibitor and activator systems of fibrinolysis. The lysis of fibrin takes place through a proteolytic reaction catalyzed by plasmin; this latter enzyme derives from the activation of plasminogen by agents called plasminogen activators. The principal components of the fibrinolytic system are outlined in the following sections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allen RA, Pepper DS (1981) Isolation and properties of human vascular plasminogen activator. Thromb Haemost 45:43–50

    PubMed  CAS  Google Scholar 

  • Ambrus JL, Ambrus CM, Pikern L, Soldes S, Bros I (1975) Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 6:433–458

    PubMed  CAS  Google Scholar 

  • Anderson JL, Marshall HN, Bray BE, Lutz JR, Frederick PR, Vanowitz FG (1983) A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 308:1312–1318

    PubMed  CAS  Google Scholar 

  • Andreasen PA, Nielsen LS, Grondahl-Hansen J, Skriver L, Zeuthen J, Stephens R, Danø K (1984) Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells identified after affinity purification with a monoclonal antibody. EMBO J 3:51–56

    PubMed  CAS  Google Scholar 

  • Astedt B (1979) No cross reaction between circulating plasminogen activator and urokinase. Thromb Res 14:535–539

    PubMed  CAS  Google Scholar 

  • Astedt B, Hamberg L, Wagner G, Richter P, Ploug J (1979) Purification of urokinase by a beta-naphthamidine affinity. Thromb Haemost 42:924–928

    PubMed  CAS  Google Scholar 

  • Astrup T (1956) Fibrinolysis in the organism. Blood 11:781–805

    PubMed  CAS  Google Scholar 

  • Astrup T (1968) Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol [Suppl] 17:241–257

    Google Scholar 

  • Baker JB, Lou DA, Simmer RL, Cunningham DD (1980) Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21:37–45

    PubMed  CAS  Google Scholar 

  • Balian G, Click EM, Crouch E, Davidson JM, Bornstein P (1979) Isolation of a collagen-binding fragment from fibronectin and cold-insoluble globulin. J Biol Chem 254:1429–1432

    PubMed  CAS  Google Scholar 

  • Barnhart MI, Riddle JM (1963) Cellular localization of Profibrinolysin (plasminogen). Blood 21:306–311

    PubMed  CAS  Google Scholar 

  • Bergquist D, Ljungher HA (1981) A comparative study of Dextran 70 and the sulphated polysaccharide in the prevention of post-operative thromboembolic complication. Br J Surg 68:449–451

    Google Scholar 

  • Bernik MB, White WF, Oller EP, Kwaan HC (1974) Immunologic identity of plasminogen activator in human urine, heart, blood vessels and tissue culture. J Lab Clin Med 84:546–558

    PubMed  CAS  Google Scholar 

  • Binder BR, Spragg J, Austen KF (1979) Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 254:1998–2003

    PubMed  CAS  Google Scholar 

  • Bogenmann E, Jones PA (1983) Role of plasminogen in matrix breakdown by neoplastic cells. INGI 71:1177–1182

    CAS  Google Scholar 

  • Brunetti L, Lotti T (1983) Study of cutaneous fibrinolytic activity after separation of epidermis from dermis. Ital Gen Rev Dermatol 22:111–116

    Google Scholar 

  • Burnard KG, Clemenson C, Morland N (1980) Venous lipodermatosclerosis treatment by fibrinolytic enhancement and elastic compression. Br Med J 280:7–11

    Google Scholar 

  • Butler WB, Kirkland WL, Jorgensen TL (1979) Induction of plasminogen activator by estrogen in a human breast cancer cell line (NCF-7). Biochem Biophys Res Commun 90:1328–1334

    PubMed  CAS  Google Scholar 

  • Camiolo SM, Thorsen S, Astrup T (1971) Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin and plasmin. Proc Soc Exp Biol Med 138:277–280

    PubMed  CAS  Google Scholar 

  • Camiolo SM, Markus G, Evers JL, Hobika GH, Depasquale JL, Beckley S, Grimaldi Jp (1981) Plasminogen activator content of neoplastic and benign human prostate tissue: fibrin augmentation of an activator activity. Int J Cancer 27:191–198

    PubMed  CAS  Google Scholar 

  • Camiolo SM, Markus G, Englander LS, Siuta MR, Hobika GH, Kohga S (1984) Plasminogen activator content and secretion in expiants of neoplastic and benign human prostate tissue. Cancer Res 44:311–318

    PubMed  CAS  Google Scholar 

  • Casslen B, Ohlsson K (1981) Cyclic variation of plasminogen activator in human uterine fluid and the influence of an intrauterine device. Acta Obstet Gynecol Scand 60:97–101

    PubMed  CAS  Google Scholar 

  • Castellino FJ, Powell JR (1981) Studies on human proteases. Methods Enzymol 80:365–378

    PubMed  CAS  Google Scholar 

  • Chimenti M, Barontini A, Lotti T, Fabbri P (1981) Fibrinolytic activity and immunopathological findings in porphyria cutanea tarda. Ital Gen Rev Dermatol 18:163–170

    Google Scholar 

  • Christman JK, Silverstein SC (1977) Plasminogen activators. In: Barrett AJ (ed) Proteinases in mammalian cells and tissues, vol 2. North-Holland, Amsterdam, pp 90–149

    Google Scholar 

  • Clemmensen I (1978) Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin. Thromb Haemost 39:616–623

    PubMed  CAS  Google Scholar 

  • Clemmensen I, Christensen F 81976) Inhibition of urokinase by complex formation with human alpha1-anti trypsin. Biochim Biophys Acta 429:591–599

    Google Scholar 

  • Cliffton EE, Grossi CE (1956) Effect of human plasmin on toxic effects and growth of blood borne metastasis of Brown-Pearce carcinoma and V2 carcinoma of rabbit. Cancer 9:1147–1152

    PubMed  CAS  Google Scholar 

  • Cole ER, Bachmann FW (1977) Purification and properties of a plasminogen activator from pig heart. J Biol Chem 252:3729–3737

    PubMed  CAS  Google Scholar 

  • Collen D (1976) Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 69:209

    PubMed  CAS  Google Scholar 

  • Collen D (1980) On the regulation and control of fibrinolysis. Eduard Kowalski Memorial Lecture. Thromb Haemost 43:77–89

    PubMed  CAS  Google Scholar 

  • Collen D (1983) Mechanism of inhibition of tissue-type plasminogen activator in blood. Thromb Haemost 50:678

    PubMed  CAS  Google Scholar 

  • Collen D, Stassen JM, Vestraete M (1983) Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of thrombus and route of administration. J Clin Invest 71:368–376

    PubMed  CAS  Google Scholar 

  • Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M (1984 a) Biological and thrombolytic properties of proenzyme and active forms of human urokinase. III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 52:27–30

    PubMed  CAS  Google Scholar 

  • Collen D, Stassen JM, Marafino BJ Jr, Builder S, de Cock F, Ogez J, Tajiri D et al. (1984 b) Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 231:146–152

    PubMed  CAS  Google Scholar 

  • Crawford GMP, Ogston D (1975) The action of antithrombin III on plasmin and activators of plasminogen. Biochim Biophys Acta 391:189

    PubMed  CAS  Google Scholar 

  • Cunliffe WJ (1968) An association between cutaneous vasculitis and decreased blood fibrinolytic activity. Br J Dermatol 84:99–112

    Google Scholar 

  • Cunliffe WJ (1978) An association between cutaneous vasculitis and decreased blood fibrinolytic activity. Lancet 1:226

    Google Scholar 

  • Cunliffe WJ, Menon IS (1969) Blood fibrinolytic activity in diseases of the small blood vessels and the effect of low molecular weight dextran. Br J Dermatol 81:220

    PubMed  CAS  Google Scholar 

  • Danø K, Reich E (1978) Serine enzymes released by cultured neoplastic cells. J Exp Med 147:745–757

    PubMed  Google Scholar 

  • Danø K, Dabelsteen E, Nielsen LS, Kaltoft K, Wilson EL, Zeuthen J (1982) Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem 39:1165–1170

    Google Scholar 

  • Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1 (44): 139–265

    Google Scholar 

  • Davidson JF, Walker ID (1979) Synthetic fibrinolytic agents. Prog Cardiovasc Dis 21:375–396

    PubMed  CAS  Google Scholar 

  • Davidson JF, Lochead M, MacDonald G A, MacNicol GP (1972) Fibrinolytic enhancement by stanozolol: a double blind trial. Br J Haematol 22:543–559

    PubMed  CAS  Google Scholar 

  • Davies MC, Englert ME, de Renzo EC (1964) Interaction of streptokinase and human plasminogen. I. Combining of streptokinase and plasminogen observed in the ultracentrifuge under a variety of experimental conditions. J Biol Chem 239:2651–2656

    PubMed  CAS  Google Scholar 

  • Dayer JM, Vassalli JD, Bobbitt JL, Hull RN, Reich E, Krane SM (1981) Calcitonin stimulates plasminogen activator in renal tubular cells. J Cell Biol 91:195–200

    PubMed  CAS  Google Scholar 

  • Del Rosso M, Dini G, Fibbi G (1985) Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. Cancer Res 45:630–636

    PubMed  Google Scholar 

  • Den Ottolander GJH, Leijnse B, Cremer-Elfrink HNJ (1967) Plasmatic and platelet anti-plasmins and antiactivator. I. Thromb Diath Haemorrh 18:404

    Google Scholar 

  • Dini G, Fibbi G, Pasquali F, del Rosso M (1985) Plasminogen activator: morphological evidence of binding internalization and delivery to lysosomes in 3T3 mouse fibroblast. Histochem J 17:333–341

    PubMed  CAS  Google Scholar 

  • Dodman D, Cunliffe WJ, Roberts BE, Sibbald R (1973) Clinical and laboratory double blind investigation on effects of fibrinolytic therapy in patients with cutaneous vasculitis. Br Med J 1:82–92

    Google Scholar 

  • Eaton DL, Baker JB (1983) Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator-antiplasmin. J Cell Biol 97:323–328

    PubMed  CAS  Google Scholar 

  • Fabbri P, Lotti T, Dindelli A, Petrini N, Cappugi P (1981) Studio della fibrinolisi tissutale e plasmatica nella vasculite cutanea necrotizzante. Ann Ital Dermatol Clin Sper 35:347–354

    Google Scholar 

  • Fabbri P, Lotti T, Panconesi E (1985) Pathogenesis of pemphigus: role of the plasminogen activator in acantholysis. Int J Dermatol 24:422–426

    PubMed  CAS  Google Scholar 

  • Fearnley JD (1966) Fibrinolysis. Arnold, London, pp 16–31

    Google Scholar 

  • Fischer AM, Merton RE, Marsh NA, Willans S, Gaffney PJ, Barrowcliffe TN, Thomas DP (1982) A comparison of pentosan polysulphate and heparin. II. Effects of subcutaneous injection. Thromb Hemost 47:109–113

    CAS  Google Scholar 

  • Fräki JE, Djupsund BM, Hopsu-Havu VK (1978) Plasminogen activators of psoriatic scale extracts. Separation of two plasminogen activators by isoelectric focusing. Arch Dermatol Res 261:259–266

    PubMed  Google Scholar 

  • Fräki JE, Briggaman RA, Lazarus GS (1982) Uninvolved skin from psoriatic patients develops signs of involved psoriatic skin after being grafted onto nude mice. Science 215:685–687

    PubMed  Google Scholar 

  • Fräki JE, Lazarus GS, Gilgor RS (1983) Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 108:39–44

    PubMed  Google Scholar 

  • Friberger P (1982) Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest [Suppl 162]42

    Google Scholar 

  • Gelehrter TD, Barouski-Miller PA, Coleman PL, Cwikel BJ (1983) Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 53–54:11–21

    PubMed  Google Scholar 

  • Gold HK, Fallon JT, Yasuda T, Leinbach RC, Kahe BA, Newall JB, Guerrero JL et al. (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 70:700–707

    PubMed  CAS  Google Scholar 

  • Golds EE, Ciosek CP Jr, Hamilton JA (1983) Differential release of plasminogen activator and latent collagenase from mononuclear cell stimulated synovial cells. Arthritis Rheum 26:15–21

    PubMed  CAS  Google Scholar 

  • Goldsmith GH Jr, Saito H, Ratnoff OD (1978) The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 62:54–60

    PubMed  CAS  Google Scholar 

  • Gordon S, Cohn ZA (1978) Bacille Calmette-Guèrin infection in the mouse. Regulation of macrophage plasminogen activator by lymphocytes and specific antigen. J Exp Med 148:1175–1188

    Google Scholar 

  • Granelli-Piperno A, Reich E (1983 a) A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 148:223–234

    Google Scholar 

  • Granelli-Piperno A, Reich E (1983 b) Plaminogen activators of the pituitary gland: enzyme characterization and hormonal modulation. J Cell Biol 97:1029–1037

    PubMed  CAS  Google Scholar 

  • Granelli-Piperno A, Vassalli JD, Reich E (1977) Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J Exp Med 146:1693–1706

    PubMed  CAS  Google Scholar 

  • Green H (1977) Terminal differentiation of cultured human epidermal cells. Cell 11:405–416

    PubMed  CAS  Google Scholar 

  • Gross JL, Moscatelli D, Jaffe EA, Rifkin DB (1982) Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol 95:974–981

    PubMed  CAS  Google Scholar 

  • Gunzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L (1982) The primary structure of high molecular mass urokinase from human urine. The complete aminoacid sequence of the A chain. Hoppe Seylers Z Physiol Chem 363:1155–1165

    PubMed  CAS  Google Scholar 

  • Gurevrich V, Pannel R, Kelley P (1985) Single-chain urokinase a 5500 M. W. zymogen precursor of urokinase with fibrin-dependent activation under physiological condition. In: Davidson JF, Cooccheri M, Donato MB (eds) progress in fibrinolysis, vol 3. Livingstone, Edinburgh, pp 352–355

    Google Scholar 

  • Halse T (1962) Aktivierung der Fibrinolyse und Thrombolyse durch Polysaccharid. Schwefelsäureester (Heparin, Herparinoide). Arzneimittelforschung 12:574–451

    PubMed  CAS  Google Scholar 

  • Hamilton J, Vassalli JD, Reich E (1976) Macrophage plasminogen activator: induction by asbestos is blocked by anti-inflammatory steroids. J Exp Med 144:1689–1694

    PubMed  CAS  Google Scholar 

  • Hashimoto K, Shafran KM; Webber PS, Lazarus GS, Singer KH (1982) Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cell A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med 157:259–272

    Google Scholar 

  • Hashimoto K, Singer KH, Shafran KM, Lazarus GS (1983) Incubation of human epidermal cell with pemphigus IgG results in an increase in plasminogen activator activity. J Invest Dermatol 81:424–429

    PubMed  CAS  Google Scholar 

  • Hashimoto K, Singer K, Lazarus GS (1984) Penicillamine induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus. Arch Dermatol 120:762–764

    PubMed  CAS  Google Scholar 

  • Haustein UF (1969) Die Lokalisation des Gewebsaktivators der Fibrinolyse bei Dermatosen. Arch Klin Exp Dermatol 234:182–194

    PubMed  CAS  Google Scholar 

  • Hawiger J (1969) Precipitation of soluble fibrin monomer complexes by lysosomal protein fraction of polymorphonuclear leucocytes. Proc Soc Exp Biol Med 131:349

    PubMed  CAS  Google Scholar 

  • Heisel M, Laug WE, Jones PA, Stowe SM (1984) Effect of X-irradiation on artificial blood vessel wall degradation by invasive tumor cells. Cancer Res 44:2441–2445

    PubMed  CAS  Google Scholar 

  • Hilgard P, Hiemeyer V (1970) Fibrinolysis, thromboplastin activity and localization of radioiodinated fibrinogen in experimental tumors. Eur J Cancer 6:157–158

    PubMed  CAS  Google Scholar 

  • Isseroff RR, Rifkin DB (1982) Plasminogen is present in the basal layer of epidermis. Clin Res 30:605A

    Google Scholar 

  • Isseroff RR, Rifkin DB (1983) Plasminogen is present in the basal layer of epidermis. J Invest Dermatol 80:297–299

    PubMed  CAS  Google Scholar 

  • Isseroff RR, Fusening NE, Rifkin DB (1982) Plasminogen activator in differentiating mouse keratinocytes. J Invest Dermatol 80:217–222

    Google Scholar 

  • Jaken S, Black P (1981 a) Regulation of plasminogen activator in 3T3 cells: effect of phorbol myristate acetate on subcellular distribution and molecular weight. J Cell Biol 90:727–731

    PubMed  CAS  Google Scholar 

  • Jaken S, Black P (1981 b) Correlation between a specific molecular weight form of plasminogen activator and metabolic activity of 3T3 cells. J Cell Biol 90:721–726

    PubMed  CAS  Google Scholar 

  • Jarrett PEM, Morland M, Browse NL (1978) Treatment of Raynaud’s phenomenon by fibrinolytic enhancements. Br Med J 2:523–525

    PubMed  CAS  Google Scholar 

  • Jones PA, de Clerck A (1980) Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. Cancer Res 40:3222–3227

    PubMed  CAS  Google Scholar 

  • Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52000 plasminogen activating enzyme. Proc Natl Acad Sci USA 79:3720–3723

    PubMed  CAS  Google Scholar 

  • Kaplan AP, Austen KF (1972) The fibrinolytic pathway of human plasma, isolation and characterization of plasminogen proactivator. J Exp Med 136:1378–1393

    PubMed  CAS  Google Scholar 

  • Kaplan AP, Castellino FJ, Collen D, Wiman B, Taylor FB Jr (1978) Molecular mechanisms of fibrinolysis in man. Thromb Haemost 39:263–283

    PubMed  CAS  Google Scholar 

  • Katz J, Troll W, Levy M, Filkins K, Russo J, Levitz M (1976) Estrogen dependent trypsin-like activity in the rat uterus. Localization of activity in the 12000 g pellet and nucleus. Arch Biochim Biophys 173:347–354

    CAS  Google Scholar 

  • Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984) Proactivites, estrogen receptor interactions, and plasminogen activator — inducing activities of tamoxifen and hydroxy tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112–119

    PubMed  CAS  Google Scholar 

  • Klimetzek V, Sorg C (1977) Lymphokine-induced secretion of plasminogen activator by murine macrophages. Eur J Immunol 7:185–187

    PubMed  CAS  Google Scholar 

  • Kline DL (1971) Significance of fibrinolysis occurring in patient with metastatic cancer. In: Bang NV, Beller FK, Deutsch E, Mammen EF (eds) Thrombosis bleeding disorders. Academic, New York, pp 358–360

    Google Scholar 

  • Kline DL, Reddy KNN (1977) Proactivator and activator levels of plasminogen in plasma as measured by caseinolysis. J Lab Clin Med 89:1153–1158

    PubMed  CAS  Google Scholar 

  • Klöcking HP, Markwardt F (1984) Pentosan polysulphate-induced release of plasminogen activator. Haemostasis 14:121

    Google Scholar 

  • Kristensen O, Larsson LI, Nielsen LS, Grøndahl-Hansen J, Andreasen PA, Danø K (1984) Human endothelial cells contain one type of plasminogen activator. FEBS Lett 168:33–37

    PubMed  CAS  Google Scholar 

  • Lacroix M, Fritz IB (1977) The control of the synthesis and secretion of plasminogen activator by rat Sertoli cells in culture. Mol Cell Endocrinol 9:227–236

    PubMed  CAS  Google Scholar 

  • Larsson LI, Skriver L, Nielsen LS, Grøndahl-Hansen J, Kristensen P, Danø K (1984) Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 98:894–903

    PubMed  CAS  Google Scholar 

  • Lee LS, Weinstein IB (1978) Epidermal growth factor, like phorbol esters, induced plasminogen activator in Hela cells. Nature 274:696–697

    PubMed  CAS  Google Scholar 

  • Lijnen HR, Collen D (1982) Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemost 8:2–10

    PubMed  CAS  Google Scholar 

  • Lin HS, Gordon S (1979) Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factor. J Exp Med 150:231–245

    PubMed  CAS  Google Scholar 

  • Ljungner H, Holmberg L, Kjeldgaard A, Nilsson IM, Astedt B (1983) Immunological characterization of plasminogen activator in the human vessel wall. J Clin Pathol 36:1046–1049

    PubMed  CAS  Google Scholar 

  • Lobel P, Schror K (1985) Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn Schmiedebergs Arch Pharmacol 331:125

    PubMed  CAS  Google Scholar 

  • Loskutoff DJ, Edgington TS (1977) Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 74:3903–3907

    PubMed  CAS  Google Scholar 

  • Loskutoff DJ, von Mourik JA, Erickson LA, Lawrence D (1983) Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 80:2956–2960

    PubMed  CAS  Google Scholar 

  • Lotti T, Fabbri P (1981) Investigation on cutaneous fibrinolytic activity in cumulative irritant contact dermatitis. Ital Gen Rev Dermatol 18(2–3): 195–203

    Google Scholar 

  • Lotti T, Fabbri P (1984) Studio degli attivatori e degli inhibitori della fibrinolisi nel lichen planus. Ital Dermatol Venereol 19:97–103

    Google Scholar 

  • Lotti T, Fabbri P (1985) Investigation on coagulation and fibrinolysis in Kaposi’s sarcoma. In: Cerimele D (ed) Kaposi’s sarcoma. Spectrum, New York, pp 117–130

    Google Scholar 

  • Lotti T, Dindelli A, Barontini A, Fabbri P (1979) Fibrin deposits and fibrinolytic activity in certain dermatoses with immunological pathogenesis. III. Experimental results. Ital Gen Rev Dermatol 16(2–3): 197–205

    Google Scholar 

  • Lotti T, Dindelli A, Fabbri P (1980) Cutaneous fibrinolysis: a modified method of autohis-tographic identification of plasminogen activators in tissue. Technical note. Ital Gen Rev Dermatol 17:157–160

    Google Scholar 

  • Lotti T, Brunetti L, Casigliani R, Romani A, Fabbri P (1983) A new technique for detecting inhibitors of fibrinolysis in skin section. Technical note. Ital Gen Rev Dermatol 20:105–109

    Google Scholar 

  • Lotti T, Cappugi P, Lattari P, Panconesi E (1984 a) Increased cutaneous fibrinolytic activity in a case of aquagenic pruritus. Int J Dermatol 23:61–62

    PubMed  CAS  Google Scholar 

  • Lotti T, Fabbri P, Panconesi E, Angiolini P, del Rosso M, Dini G, Fabbri G (1984 b) Urokinase receptors on human keratinocytes. Ital Gen Rev Dermatol 21:101–104

    Google Scholar 

  • Lotti T, Fabbri P, Brunetti L, Palombi C, Rossi P, Vallecchi C (1985 a) Cutaneous plasminogen activator activity in melanoma basal cell and squamous cell carcinoma. Ital Gen Rev Dermatol 22:89–95

    Google Scholar 

  • Lotti T, Battini ML, Zuccati G, Fabbri P (1985 b) L’attività fibrinolitica cutanea nelle porpore infantili di Majocchi e Schamberg. G Ital Dermatol Venereol 2:39–45

    Google Scholar 

  • Lotti T, Fabbri P, Panconesi E (1985 c) Cutaneous fibrinolytic activity in urticaria and vasculitis. In: Champion RH et al. (eds) The urticarias. Livinstone, Edinburgh, pp 161–167

    Google Scholar 

  • Lotti T, Brunetti L, Panconesi E (1986 a) A novel action of anthralin (Letter). Arch Dermatol 122:748–749

    PubMed  CAS  Google Scholar 

  • Lotti T, Steinman HK, Grevaes MW, Fabbri P, Brunetti L, Panconesi E (1986 b) Increased cutaneous fibrinolytic activity in aquagenic pruritus. Int J Dermatol 25:508–511

    PubMed  CAS  Google Scholar 

  • Lotti T, Fabbri P, Panconesi E (1987 a) The pathogenesis of venous ulcers (Letter). J Am Acad Dermatol 16:877–879

    PubMed  CAS  Google Scholar 

  • Lotti T, Fabbri P, Bonan P, Panconesi E (1987 b) Evaluation of the cutaneous plasminogen activators in pemphigus vulgaris. Technical note. Ital Gen Rev Dermatol 24:75–79

    Google Scholar 

  • Lotti T, Bonan P, Panconesi E (1988) Epidermal plasminogen activator activity tPA dependent is a marker of disease activity in psoriasis (Letter). J Invest Dermatol 90:86–87

    PubMed  CAS  Google Scholar 

  • Low DA, Baker JB, Koonee WC, Cunningham DD (1981) Released protease-nexin regulates cellular binding internalization, and degradation of serine proteases. Proc Natl Acad Sci USA 78:2340–2344

    PubMed  CAS  Google Scholar 

  • Mackie M, Booth NA, Bennett B (1981) Comparative studies on human activators of plasminogen. Br J Haematol 47:77–90

    PubMed  CAS  Google Scholar 

  • Markus G, Werkheiser WC (1964) The interaction of streptokinase with plasminogen. I. Functional properties of the activated enzyme. J Biol Chem 239:2637–2643

    PubMed  CAS  Google Scholar 

  • Marrack D, Kubala M, Corry P, Leavens M, Howze J, Dewey W, Bale WF, Spar IL (1967) Localization of intracranial tumors. Comparative study with 131-I-labeled antibody to human fibrinogen and neohydrin-203Hg. Cancer 20:751–755

    PubMed  CAS  Google Scholar 

  • Matsuo O, Rijken DC, Collen D (1981) Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291:590–591

    PubMed  CAS  Google Scholar 

  • Mattsson C, Nyberg-Arrhenius V, Wallen P (1981) Dissolution of thrombi by tissue plasminogen activator urokinase and streptokinase in an artificial circulating system. Throm Res 21:535–545

    CAS  Google Scholar 

  • Menon IS, Cunliffe WJ (1969) Phenformin and ethyloestrenol for Raynaud’s disease. Lancet 2:1135–1149

    PubMed  CAS  Google Scholar 

  • Mira-Y-Lopez R, Reich E, Ossowski L (1983) Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors. Cancer Res 43:5467–5477

    PubMed  CAS  Google Scholar 

  • Miwa N, Takavanagi S, Suzuki A (1981) Comparative studies on two active enzyme forms of human urinary urokinase. I. Purification by serial column chromatography and homogeneity analyses of molecular weight and isoelectric point. Chem Pharm Bull (Tokyo) 29:463–671

    CAS  Google Scholar 

  • Morioka S, Jensen PJ, Lazarus GS (1984) Localization of human keratinocyte plasminogen activator with anti-urokinase antibody (Abstr). J Invest Dermatol 82:393

    Google Scholar 

  • Moudy GH (1982) The source of plasminogen activator in human saliva. Arch Oral Biol 27:33–37

    Google Scholar 

  • Müllertz S, Lassen M (1953) An activator system in blood indispensable for formation of plasmin by streptokinase. Proc Soc Exp Biol Med 82:264–268

    PubMed  Google Scholar 

  • Nagy B, Ban J, Bardar B (1977) Fibrinolysis associated with human neoplasia. Production of plasminogen activator by human tumors. Int J Cancer 19:614–620

    PubMed  CAS  Google Scholar 

  • Neri-Serneri GG (1981) Malattie emorragiche e trombotiche. SEU Rome, pp 173–177

    Google Scholar 

  • Neumann C, Sorg C (1983) Regulation of plasminogen activator secretion by interferon induction and proliferation in murine macrophages. Eur J Immunol 13:143–147

    PubMed  CAS  Google Scholar 

  • Newstead GL, Griffiths JD, Salsbury AJ (1976) Fibrinolytic activity of carcinoma of the colorectum. Surg Gynecol Obstet 143:61–64

    PubMed  CAS  Google Scholar 

  • Niada R, Mantovani M, Prino G, Pescador R, Berti F, Omini C, Foleo GC (1981) Antithrombotic activity of a polydesoxyribonucleotidic extracts from organs: a possible link with prostacyclin. Thromb Res 23:233

    PubMed  CAS  Google Scholar 

  • Nielsen LJ, Hansen JG, Skriver L, Wilson EL, Kalfoft K, Zeuthen J, Danø K (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 24:6410–6415

    Google Scholar 

  • Niewiarowski S, Goldstein S (1973) Interaction of cultured human fibroblast with fibrin: modification by drugs and aging in vitro. J Lab Clin Med 82:605–610

    PubMed  CAS  Google Scholar 

  • Noordhoek-Hegt V, Brakmam P (1974 a) Histochemical study of an inhibitor of fibrinolysis in the human arterial wall. Nature 248:75–76

    CAS  Google Scholar 

  • Noordhoek-Hegt V, Brakman P (1974 b) Inhibition of fibrinolysis by the human vascular wall related to the presence of smooth muscle cells. Haemostasis 3:118–128

    Google Scholar 

  • Ofosu FA, Hodi GJ, Smith LM, Cerkus AL, Hirsh J, Blajchman MA (1984) Heparan sulfate and dermatan-sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 54:727–747

    Google Scholar 

  • Ogawa N, Yamamoto M, Katamine T, Tajima H (1975) Purification and some properties of urokinase. Thromb Diath Haemorrh 34:194–209

    PubMed  CAS  Google Scholar 

  • Ogston D, Bennet NB, Herbert RJ, Douglas AS (1973) The inhibition of urokinase by alfa-2-macroglobulin. Clin Sci 44:73–79

    PubMed  CAS  Google Scholar 

  • Ogston D, Bennet NB, Mackie M (1976) Properties of a partially purified preparation of a circulating plasminogen activator. Thromb Res 8:275

    PubMed  CAS  Google Scholar 

  • Ossowski L, Biegel D, Reich E (1979) Mammary plasminogen activator correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 16:929–940

    PubMed  CAS  Google Scholar 

  • Panconesi E, Fabbri P, Lotti T, Troiano G (1982) Cutaneous fibrinolytic activity in bullous diseases. Ital Gen Rev Dermatol 19:19–28

    Google Scholar 

  • Peltz SW, Katzenellenbogen BS, Kneifel MA, Mangel WF (1983) Plasminogen activators in tissues of the immature and estrogen stimulated rat uetrus and in uterine luminal fluid: characterization and properties. Endocrinology 112:890–897

    PubMed  CAS  Google Scholar 

  • Pennica D, Collen D, Holmes WE, Kohr WJ, Harkin SRN, Yehar GA, Ward CA et al. (1983) Cloning and expression of human tissue type plasminogen activator c-DNA in E. coli. Nature 301:214–221

    PubMed  CAS  Google Scholar 

  • Plow EF, Edginton TS (1973) Discriminating neoantigenic differences between fibrinogen and fibrin derivatives. Proc Natl Acad Sci USA 70:1169–1175

    CAS  Google Scholar 

  • Plow EF, Edginton TS (1975) An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56:30–38

    PubMed  CAS  Google Scholar 

  • Plow EF, Hougie C, Edgington TS (1971) Neoantigenic expression engendered by plasmin cleavage of fibrinogen. J Immunol 197:1455–1463

    Google Scholar 

  • Poggi A, Polentarutti N, Donati MB, de Gaetano G, Garattini S (1977) Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res 37:272–277

    PubMed  CAS  Google Scholar 

  • Pollack R, Rifkin D (1975) Actin-containing tables within anchorage-dependent rat embryo cells are dissociated by plasmin and trypsin. Cell 6:495–506

    Google Scholar 

  • Prowse CV, Cash JD (1984) Physiologic and pharmacologic enhancements of fibrinolysis. Semin Thromb Hemost 10:51–60

    PubMed  CAS  Google Scholar 

  • Quigley JP (1979) Proteolytic enzymes of normal and malignant cells. In: Hynes RD (ed) Surfaces of normal and malignant cells. Wiley, New York, pp 247–285

    Google Scholar 

  • Ranby M, Bergsdorf N, Pohl G, Wallen P (1982 a) Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett 146:289–292

    PubMed  CAS  Google Scholar 

  • Ranby M, Bergsdorf N, Nilsson T (1982 b) Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 27:175–183

    PubMed  CAS  Google Scholar 

  • Reddy KNN, Markus G (1972) Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. J Biol Chem 247:1683–1691

    PubMed  CAS  Google Scholar 

  • Reich E (1978) Activation of plasminogen: a general mechanism for producing extracellular proteolysis. In: Berlin RD, Herrman H, Lepow IH, Tanzer JM (eds) Molecular basis of biological degradative processes. Academic, New York, pp 155–169

    Google Scholar 

  • Rifkin DB (1978) Plasminogen activator synthesis by cultured human embryonic lung cells: characterization of the suppressive effect of corticosteroids. J Cell Physiol 97:421–428

    PubMed  CAS  Google Scholar 

  • Rifkin DB, Crowe RM (1980) Studies on the control of plasminogen activators production by cultured human embryonic lung cells: requirements for inhibition by corticosteroids. J Cell Physiol 105:417–422

    PubMed  CAS  Google Scholar 

  • Rifkin DB, Loeb JN, Moore G, Reich E (1974) Properties of plasminogen activators formed by neoplastic human cell in culture. J Exp Med 139:1317–1328

    PubMed  CAS  Google Scholar 

  • Rijken DC, Collen D (1981) Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256:7035–7041

    PubMed  CAS  Google Scholar 

  • Rijken DC, Wijangaa RDS, Welbergen J (1980) Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 18:815–830

    PubMed  CAS  Google Scholar 

  • Rijken DC, Wijangaa RDS, Welbergen J (1981) Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 97:477–486

    PubMed  CAS  Google Scholar 

  • Robbins KC, Summaria L (1970) The structure of human plasminogen. Methods Enzymol 19:184–199

    Google Scholar 

  • Robbins KC, Summaria L, Hsieh B, Shah RJ (1967) The peptide chains of human plasminogen to plasmin. J Biol Chem 242:2333–2342

    PubMed  CAS  Google Scholar 

  • Ryan TJ (1973) Inflammation, fibrin and fibrinolysis. In: Jarrett E (ed) The physiology and pathophysiology of the skin, vol 2. Academic, London, pp 445–477

    Google Scholar 

  • Ryan TJ (1976) Microvascular injury. Saunders, Oxford, pp 317–319

    Google Scholar 

  • Ryan TJ (1980) Microcirculation in psoriasis and tissue fluid. Pharmacol Ther 10:27

    PubMed  CAS  Google Scholar 

  • Saba HI, Roberts HR, Helion JC (1967) The anticoagulant activity of lysosomal cationic proteins from polymorphonuclear leukocytes. J Clin Invest 46:580

    PubMed  CAS  Google Scholar 

  • Saba HI, Roberts HR, Helion JC (1968) Antiheparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes. Blood 31:369

    PubMed  CAS  Google Scholar 

  • Saito H, Hamilton SM, Tavill AS, Louis L, Ratnoff OD (1980) Production and release of plasminogen by isolated perfused rat liver. Proc Natl Acad Sci USA 77:6837–6840

    PubMed  CAS  Google Scholar 

  • Saksela O (1981) Radial caseinolysis in agarose: a simple method for detection of plasminogen activator in the presence of inhibitory substances and serum. Anal Biochem 111:276–282

    PubMed  CAS  Google Scholar 

  • Sasahara AA, Ho DD, Sharma GVRK (1979) When and how to use fibrinolytic agents. Drug Ther 9:111–128

    Google Scholar 

  • Schroder EW, Chou IN, Black PH (1980) Effects of retinoic acid on plasminogen activator and mitogenic responses of cultured mouse cells. Cancer Res 40:3089–3094

    PubMed  CAS  Google Scholar 

  • Scott RW, Baker JB (1983) Purification of human protease nexin. J Biol Chem 258:10438–10444

    Google Scholar 

  • Searls DB (1980) An improved colorimetric assay for plasminogen activator. Anal Biochem 107:64–70

    PubMed  CAS  Google Scholar 

  • Shepro D, Schleef R, Hechtman HB (1980) Plasminogen activator activity by cultured bovine aortic endothelial cells. Life Sci 26:415–422

    PubMed  CAS  Google Scholar 

  • Singer KH, Lazarus GS (1983) Molecular mechanism of pathogenesis. Clin Dermatol 1(2):196–221

    Google Scholar 

  • Skriver L, Larsson LI, Kielberg U, Nielsen LS, Andreasen PB, Kristensen P, Danø K (1984) Immunocytochemical localization of urokinase type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99:752–757

    Google Scholar 

  • Soreq H, Miskin R (1983) Modulation in the levels and localization of plasminogen activator in differentiating neuroblastoma cells. Dev Brain Res 11:149–158

    CAS  Google Scholar 

  • Strassburger W, Wollmer A, Pitts JE, Glover ID, Tickle IJ, Blundell TL, Steffens GJ et al. (1983) Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett 157:219–223

    PubMed  CAS  Google Scholar 

  • Summaria L, Wohl RC, Boreisha IG, Robbins KC (1982) A virgin enzyme derived from human plasminogen. Specific cleavage of the arginyl-560-valyn peptide bond in the diisopropoxyphosphinyl virgin enzyme by plasminogen activators. Biochemistry 21:2056–2059

    PubMed  CAS  Google Scholar 

  • Svanberg L, Linell F, Pandolfi M, Asted B (1975) Plasminogen activators in ovarian tumours. Acta Pathol Microbiol Scand [A] 83:193–198

    CAS  Google Scholar 

  • Thorsen S, Müllertz S (1974) Rate of activation and electrophoretic mobility of unmodified and partially degraded plasminogen. Effects of 6-aminohexanoic acid and related compounds. Scand J Clin Lab Invest 34:167–176

    PubMed  CAS  Google Scholar 

  • Todd AS (1959) The histological localization of fibrinolysis activator. J Pathol Bacteriol 78:281–283

    PubMed  CAS  Google Scholar 

  • Toki N, Tsushima H, Yamasaki M, Yamasaki R, Yamura T (1982) Isolation of tissue plasminogen activator from skin lesions with allergic vasculitis. J Invest Dermatol 78:18–23

    PubMed  CAS  Google Scholar 

  • Troll W, Rossman T, Katz J, Levitz M, Sugimura T (1975) Tumorigenesis in mouse skin: inhibition by synthetic inhibitors of proteases. In: Reich E, Rifkin DB, Show E (eds) Proteases and biological control. Cold Spring Harbor Laboratories, Cold Spring Harbor, pp 977–987

    Google Scholar 

  • Turner RH, Kurban AK, Ryan TJ (1969 a) Inhibition of fibrinolysis by human epidermis. Nature 223:841–843

    PubMed  CAS  Google Scholar 

  • Turner RH, Kurban AK, Ryan TJ (1969 b) Fibrinolytic activity in human skin following epidermal injury. J Invest Dermatol 53:458–460

    PubMed  CAS  Google Scholar 

  • Vaheri A, Ruoslahti E, Mosher DF (1978) Fibroblast surface protein. Ann NY Acad Sci 312:111–116

    Google Scholar 

  • Vassalli JD, Hamilton J, Reich E (1976) Macrophage plasminogen activator enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides. Cell 8:271–281

    PubMed  CAS  Google Scholar 

  • Vassalli JD, Granelli-Piperno A, Reich E (1978) Macrophage plasminogen activator. In: Horton JE, Tarpley TM, Davies WF (eds) Mechanisms of localized bone loss. Information Retrieval, Washington, pp 201–212

    Google Scholar 

  • Verheijen JH, Rijken DC, Changer GTG, Preston FE, Kluft C (1985) Decreased level of rapid tissue type plasminogen activator inhibition by oral administration of stanozolol. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis. VII. Livingstone, Edinburgh, pp 102–104

    Google Scholar 

  • Vetterlein D, Calton GJ (1983) Purification of urokinase from complex mixtures using immobilized monoclonal antibody against urokinase light chain. Thromb Haemost 49:24–27

    PubMed  CAS  Google Scholar 

  • Von Kaulla KN (1963) Chemistry of thrombolysis: fibrinolytic enzymes. Thomas, Springfield, pp 23–37

    Google Scholar 

  • Wallen P (1977) Activation of plasminogen with urokinase and tissue activator. In: Paoletti R, Sherrys(eds) Thrombosis and urokinase. Academic, New York, pp 91–102

    Google Scholar 

  • Wallen P, Kok P, Ranby M (1978) The tissue activator of plasminogen. In: Magnusson S, Ottesen B, Foltman B, Danø K, Neurath H (eds) Regulatory proteolytic enzymes and their inhibition. Pergamon, Oxford, pp 127–135

    Google Scholar 

  • Wallen P, Bergsdorf N, Ranby M (1982) Purification and identification of two structural variants of bovine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 719:318–328

    PubMed  CAS  Google Scholar 

  • Wallen P, Pohl G, Bergsdorf M, Ranby M, Ny T, Jörnvall H (1983) Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 132:681–686

    PubMed  CAS  Google Scholar 

  • Werb Z (1978) Biochemical actions of glucocorticoids on macrophages in culture specific inhibition of elastase, collagenase and plasminogen activator secretion and effects on other metabolic function. J Exp Med 147:1695–1712

    PubMed  CAS  Google Scholar 

  • White WF, Barlow GH, Hozen MN (1966) The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5:2160–2169

    PubMed  CAS  Google Scholar 

  • Wigler M, Weinstein TB (1976) Tumor promotor induces plasminogen activator. Nature 259:232–233

    PubMed  CAS  Google Scholar 

  • Wilson EL, Dowdle E (1978) Secretion of plasminogen activator by normal, reactive and neoplastic human tissue cultured in vitro. Int J Cancer 22:390–399

    PubMed  CAS  Google Scholar 

  • Wilson EL, Reich E (1978) Plasminogen activator in chick fibroblasts: induction of synthesis by retinoic acid synergism with viral transformation and phorbol ester. Cell 15:385–399

    PubMed  CAS  Google Scholar 

  • Wilson EL, Jacobs P, Dowdle EB (1983) The secretion of plasminogen activator by human myeloid leukemic cells in vitro. Blood 61:568–574

    PubMed  CAS  Google Scholar 

  • Wun TC, Ossowski L, Reich E (1982) A proenzyme form of human urokinase. J Biol Chem 257:7262–7268

    PubMed  CAS  Google Scholar 

  • Yuen P, Kwaan HC (1983) Fibrinolytic activity in human tumor tissue. Cancer Invest 1:369–378

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Panconesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Lotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Institute of Dermatology, St. Thomas’s Hospital, Lambeth Palace Road, SE1 7EH, London, Great Britain

    Malcolm W. Greaves M.D., Ph.D., F.R.C.P.

  2. Department of Dermatology, The Royal Victoria Infirmary, The University of Newcastle upon Tyne, NE1 4LP, Newcastle upon Tyne, Great Britain

    Sam Shuster M.D., Ph. D., F.R.C.P.

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Panconesi, E., Lotti, T. (1989). Fibrinolysis and Fibrinolytic Drugs. In: Greaves, M.W., Shuster, S. (eds) Pharmacology of the Skin II. Handbook of Experimental Pharmacology, vol 87 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74054-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74054-1_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-74056-5

  • Online ISBN: 978-3-642-74054-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation